Results of the Annual General Meeting 2024 for the financial year 2022/23 of
BRAIN Biotech AG

EQS-News: BRAIN Biotech AG / Key word(s): AGM/EGM
Results of the Annual General Meeting 2024 for the financial year 2022/23 of
BRAIN Biotech AG

12.03.2024 / 17:17 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Results of the Annual General Meeting 2024 for the financial year 2022/23 of
BRAIN Biotech AG

* Face-to-face event at the Zwingenberg site

* Executive Board and Supervisory Board approved by a clear majority

  * Silent partnership with the State of Hesse approved by a very large
    majority

Zwingenberg, Germany, 12 March 2024 - At today´s Annual General Meeting of
BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN
5203949), the shareholders approved all items on the agenda with a clear
majority.

The establishment of silent partnerships between BRAIN Biotech AG and Hessen
Kapital I GmbH and MBG H Mittelständische Beteiligungsgesellschaft Hessen
mbH - for the financing of innovative research projects at the locations in
Hesse - received approval rates of over 99% in each case.

65,99 % of the share capital was represented at the time of the voting.

In his speech to shareholders, CEO Adriaan Moelker said: 'We now have the
architecture, the employees, the technology, the customers and the products
to further accelerate our economic success. I am confident that we will
succeed in achieving our main targets: double-digit sales growth, EBITDA of
15 % +/- 5 percentage points and positive operating cash flow within our
planning horizon of five years.' In its first quarterly figures for the
2023/24 financial year, the company recently announced a quantitative
guidance for the full year with turnover to rise to EUR 58 million to EUR 62
million.

Dr Michael Majerus, Chairman of the Supervisory Board, emphasized: 'I was
very pleased to be able to hold my first Annual General Meeting as Chairman
in the form of a face-to-face event in direct contact with the
shareholders.' Majerus continued: 'In the past financial year 2022/23, BRAIN
Biotech achieved the best revenue and adjusted EBITDA figures since the
company's IPO. On this basis, the Supervisory Board supports the measures
taken by the Management Board to exploit the Group's diverse potential with
the aim of further increasing revenues and earnings and achieving the
communicated mid-term targets.'

The detailed voting results and all other documents relating to the Annual
General Meeting are available on the BRAIN Biotech website at:
https://www.brain-biotech.com/investors/financial-publications/2022-23

+++

Photo download: https://www.brain-biotech.de/en/press/


About BRAIN Biotech

BRAIN Biotech AG is a leading European supplier of biobased products and
solutions such as enzymes and proteins, microbial production strains,
natural compounds and biotechnological solutions for more sustainable
industrial processes. The company focuses on the fields of nutrition, health
and environment.

BRAIN Biotech AG is the parent company of the international BRAIN Biotech
Group. The Group's business activities are divided into three segments: The
BioProducts segment comprises the product business with specialty enzymes
and other proteins, for which the Group operates fermentation facilities in
the United Kingdom and production facilities in continental Europe and the
United States. The BioScience segment offers research-intensive custom
solutions based on enzyme technology, strain development, bioprocess
development and natural product screening. The BioIncubator segment conducts
its own R&D projects or those initiated with partners with high value-added
potential. A particularly promising incubator project is the development of
the Company's own CRISPR-based gene editing technology platform, which is
currently being established and expanded by Akribion Genomics (in foundation
planning).

Through its own R&D activities, BRAIN Biotech Group is continuously
expanding its product portfolio in the field of specialty enzymes and small
molecules. The latter are the starting point for screenings, e.g. for novel
drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt
Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities
identification number: ISIN DE0005203947 / WKN 520394). The company employs
approximately 330 people and generated revenues of EUR 55.3 million in the
fiscal year 2022/23.

For more information, please visit: https://www.brain-biotech.com, LinkedIn,
Threads and YouTube.

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

Contact Media

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN Biotech AG, and are based on information currently available to the
management.

Forward-looking statements are no guarantees of future performance, and
entail both known and unknown risks as well as uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. Numerous factors exist that could
influence the future performance of and future developments at BRAIN Biotech
AG and the BRAIN Biotech Group. Such factors include, but are not limited
to, changes in the general economic and competitive environment, risks
associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any
forward-looking statements.


---------------------------------------------------------------------------

12.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        BRAIN Biotech AG
                   Darmstädter Straße 34-36
                   64673 Zwingenberg
                   Germany
   Phone:          +49 (0) 62 51 / 9331-0
   Fax:            +49 (0) 62 51 / 9331-11
   E-mail:         ir@brain-biotech.com
   Internet:       www.brain-biotech.com
   ISIN:           DE0005203947
   WKN:            520394
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1857077

End of News EQS News Service
---------------------------------------------------------------------------

1857077 12.03.2024 CET/CEST